{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:42:31Z","timestamp":1791042151495,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T00:00:00Z","timestamp":1268092800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1038\/ijo.2010.38","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T10:08:00Z","timestamp":1268129280000},"page":"1243-1254","source":"Crossref","is-referenced-by-count":64,"title":["A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study"],"prefix":"10.1038","volume":"34","author":[{"given":"J","family":"Proietto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rissanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J B","family":"Harp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Erondu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Suryawanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M E","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A O","family":"Johnson-Levonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S B","family":"Heymsfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K D","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Amatruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,9]]},"reference":[{"key":"BFijo201038_CR1","unstructured":"Clinical guidelines on the identification, evaluation treatment of overweight obesity in adults\u2014the evidence report national institutes of health. Obes Res 1998; 6 (Suppl 2): 51S\u2013209S."},{"key":"BFijo201038_CR2","first-page":"1","volume":"894","author":"WHO","year":"2008","unstructured":"WHO. Obesity:preventing and managing the global epidemic. Report of a WHO consultant. World Health Organ Tech Rep Ser 2000 2008; 894: 1\u2013253.","journal-title":"World Health Organ Tech Rep Ser 2000"},{"key":"BFijo201038_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3109\/9781420051452","volume-title":"Handbook of Obesity: Clinical Applications","author":"GA Bray","year":"2008","unstructured":"Bray GA . Medical Mangement of Obesity. In: Bray GA, Bouchard C. (eds). Handbook of Obesity: Clinical Applications. Informa Healthcare: New York, NY, 2008. pp 227\u2013484."},{"key":"BFijo201038_CR4","doi-asserted-by":"publisher","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","volume":"142","author":"Z Li","year":"2005","unstructured":"Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532\u2013546.","journal-title":"Ann Intern Med"},{"key":"BFijo201038_CR5","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"JP Despres","year":"2005","unstructured":"Despres JP, Golay A, Sjostrom L . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121\u20132134.","journal-title":"N Engl J Med"},{"key":"BFijo201038_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"FX Pi-Sunyer","year":"2006","unstructured":"Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J . Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761\u2013775.","journal-title":"JAMA"},{"key":"BFijo201038_CR7","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","volume":"335","author":"D Rucker","year":"2007","unstructured":"Rucker D, Padwal R, Li SK, Curioni C, Lau DC . Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194\u20131199.","journal-title":"BMJ"},{"key":"BFijo201038_CR8","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","volume":"368","author":"AJ Scheen","year":"2006","unstructured":"Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF . Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660\u20131672.","journal-title":"Lancet"},{"key":"BFijo201038_CR9","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"LF Van Gaal","year":"2005","unstructured":"Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389\u20131397.","journal-title":"Lancet"},{"key":"BFijo201038_CR10","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1093\/eurheartj\/ehn076","volume":"29","author":"LF Van Gaal","year":"2008","unstructured":"Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O . Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J 2008; 29: 1761\u20131771.","journal-title":"Eur Heart J"},{"key":"BFijo201038_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cmet.2007.11.012","volume":"7","author":"C Addy","year":"2008","unstructured":"Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008; 7: 68\u201378.","journal-title":"Cell Metab"},{"key":"BFijo201038_CR12","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB . The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606\u2013613.","journal-title":"J Gen Intern Med"},{"key":"BFijo201038_CR13","unstructured":"Addy C, Cote J, Li S, Agrawal N, Majumdar A, Li H et al. Taranbant plasma concentrations are increased when co-administered with ketoconazole or ditiazem. Obesity, Program Abstract Supplement 2007; A147."},{"key":"BFijo201038_CR14","first-page":"367","volume":"32","author":"SD Keller","year":"1997","unstructured":"Keller SD, Bayliss MS, Ware Jr JE, Hsu MA, Damiano AM, Goss TF . Comparison of responses to SF-36volume: health survey questions with one-week and four-week recall periods. Health Serv Res 1997; 32: 367\u2013384.","journal-title":"Health Serv Res"},{"key":"BFijo201038_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/oby.2001.13","volume":"9","author":"RL Kolotkin","year":"2001","unstructured":"Kolotkin RL, Crosby RD, Kosloski KD, Williams GR . Development of a brief measure to assess quality of life in obesity. Obes Res 2001; 9: 102\u2013111.","journal-title":"Obes Res"},{"key":"BFijo201038_CR16","volume-title":"WAIS-III WMS-III Technical Manual","author":"D Wechsler","year":"1997","unstructured":"Wechsler D . WAIS-III WMS-III Technical Manual. The Psychological Corporations, Harcout Brace and Company: San Antonia, TX, 1997."},{"key":"BFijo201038_CR17","volume-title":"Manual for the Profile of Mood States (POMS)","author":"DM McNair","year":"1971","unstructured":"McNair DM, Lorr M, Droppleman LF . Manual for the Profile of Mood States (POMS). Educational and Industrial Testing Service: San Diego, CA, 1971."},{"key":"BFijo201038_CR18","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","volume":"282","author":"RL Spitzer","year":"1999","unstructured":"Spitzer RL, Kroenke K, Williams JB . Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. primary care evaluation of mental disorders patient health questionnaire. JAMA 1999; 282: 1737\u20131744.","journal-title":"JAMA"},{"key":"BFijo201038_CR19","unstructured":"Department of Health Human Services Public Health Service Food Drug Administration Center for Drug Evaluation Research Memorandum N12. Overview for December Meeting of Psychopharmacologic Drug Advisory Committee (PDAC) Appendix 2 Request to Sponsors\u2014Advice for the pharmaceutical industry in exploring their placebo-controlled clinical trials databases for suicidality and preparing data sets for analysis by FDA. \n                    http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/briefing\/2006-4272b1-01-FDA.pdf\n                    \n                   2006; 128\u2013137."},{"key":"BFijo201038_CR20","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","volume":"164","author":"K Posner","year":"2007","unstructured":"Posner K, Oquendo MA, Gould M, Stanley B, Davies M . Columbia classification algorithm of suicide assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007; 164: 1035\u20131043.","journal-title":"Am J Psychiatry"},{"key":"BFijo201038_CR21","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","volume":"85\/7","author":"A Katz","year":"2000","unstructured":"Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85\/7: 2402\u20132410.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFijo201038_CR22","doi-asserted-by":"crossref","unstructured":"Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obesity 2010 (in press).","DOI":"10.1038\/ijo.2010.21"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ijo201038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ijo201038","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ijo201038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:24:01Z","timestamp":1684430641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ijo201038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,9]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["BFijo201038"],"URL":"https:\/\/doi.org\/10.1038\/ijo.2010.38","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,9]]}}}